Latest Biologic Stories
First Presentation of Phase 3 Data From Brodalumab Psoriasis Program THOUSAND OAKS, Calif. and LONDON, Dec.
The company leverages its keen understanding of protein purification to achieve the highest purification standards and product quality LONDON, Dec.
NEW YORK, Dec.
Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment
EDISON, N.J., Dec.
DELHI, India, December 9, 2014 /PRNewswire/ -- Access to this therapy will impact 12 million people suffering from auto immune disorders like rheumatoid arthritis,
BIRMINGHAM, Ala. and BATON ROUGE, La. and RALEIGH, N.C. and RESEARCH TRIANGLE PARK, N.C., Dec.
- A serpent whose bite was fabled to produce intense thirst.